Corporate presentation highlights platform strategy and financial metrics
MaxCyte outlined its cell-engineering platform strategy focused on non-viral electroporation for ex vivo cell and gene therapy manufacturing.
2025 revenue was USD 33 million; non-GAAP adjusted gross margin was 81%.
Cash and cash equivalents were USD 142 million as of June 30, 2026.
The strategic platform license portfolio included 29 SPL customers and 13 clinical and commercial therapies supported; CASGEVY was listed as a commercial program.
The clinical SPL pipeline included 12 active clinical programs, about USD 110 million in precommercial milestone potential, and more than USD 30 million in milestones received to date.
MXCT•
